JNJ-2113 Long-Term Extension FRONTIER 2 Study: The First & Only Investigational Targeted Oral Peptide Designed to Block the IL-23 Receptor
Time: 3:30 pm
day: Conference Day One
Details:
- IL-23 plays a critical role in pathogenic T-cell activation in moderate-to-severe plaque psoriasis (PsO) and underpins the inflammatory response in PsO and other IL-23- mediated diseases in dermatology, rheumatology and gastroenterology
- JNJ-2113 is a novel oral peptide modality with a unique MoA of binding and inhibiting the IL-23R
- In the FRONTIER 2 52-week Long-Term Extension Study following the FRONTIER 1 16-week Ph2b Study, JNJ-2113 maintained high rates of skin clearance through 52 weeks in adults with moderate-to-severe plaque PsO, and found safety consistent with FRONTIER 1
